登录 注册 会员服务 联系我们

Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine

  • Published:2024-08-19 Issue: Volume: Page:
  • ISSN:0939-5555
  • Container-title:Annals of Hematology
  • language:en
  • Short-container-title:Ann Hematol

Author:

Huang Jen-Pei,Yeh Chiu-Mei,Gong Ya-Wen,Tsai Ming-Hsuan,Lin Yi-Tsung,Tsai Chun-Kuang,Liu Chia-Jen

Funder

Ministry of Science and Technology, Taiwan

Taiwan Clinical Oncology Research Foundation

Yen Tjing Ling Medical Foundation

Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University

Taipei Veterans General Hospital

Publisher

Springer Science and Business Media LLC

Reference49 articles.

1. Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM (2019) First-line treatment of patients with indolent Non-hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up study. J Clin Oncol 37(12):984–991. https://doi.org/10.1200/JCO.18.00605

2. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent L (2013) Bendamustine plus Rituximab versus CHOP plus Rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. https://doi.org/10.1016/S0140-6736(12)61763-2

3. Braulke F, Zettl F, Ziepert M, Viardot A, Kahl C, Prange-Krex G, Korfel A, Dreyling M, Bott A, Wedding U, Reichert D, de Wit M, Hartmann F, Poeschel V, Schmitz N, Witzens-Harig M, Klapper W, Rosenwald A, Wulf G, Altmann B, Trumper L (2022) First-line treatment with Bendamustine and Rituximab for Old and Frail patients with aggressive lymphoma: results of the B-R-ENDA Trial. Hemasphere 6(12):e808. https://doi.org/10.1097/HS9.0000000000000808

4. Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A (2022) Bendamustine: a review of pharmacology, clinical use and immunological effects (review). Oncol Rep 47(6). https://doi.org/10.3892/or.2022.8325

5. Pezzullo L, Giudice V, Serio B, Fontana R, Guariglia R, Martorelli MC, Ferrara I, Mettivier L, Bruno A, Bianco R, Vaccaro E, Pagliano P, Montuori N, Filippelli A, Selleri C (2021) Real-world evidence of cytomegalovirus reactivation in non-hodgkin lymphomas treated with bendamustine-containing regimens. Open Med (Wars) 16(1):672–682. https://doi.org/10.1515/med-2021-0274
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3